1. Home
  2. TEVA vs SBAC Comparison

TEVA vs SBAC Comparison

Compare TEVA & SBAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TEVA
  • SBAC
  • Stock Information
  • Founded
  • TEVA 1901
  • SBAC 1989
  • Country
  • TEVA Israel
  • SBAC United States
  • Employees
  • TEVA N/A
  • SBAC N/A
  • Industry
  • TEVA Biotechnology: Pharmaceutical Preparations
  • SBAC Real Estate Investment Trusts
  • Sector
  • TEVA Health Care
  • SBAC Real Estate
  • Exchange
  • TEVA Nasdaq
  • SBAC Nasdaq
  • Market Cap
  • TEVA 21.2B
  • SBAC 20.2B
  • IPO Year
  • TEVA N/A
  • SBAC 1999
  • Fundamental
  • Price
  • TEVA $24.78
  • SBAC $192.33
  • Analyst Decision
  • TEVA Strong Buy
  • SBAC Buy
  • Analyst Count
  • TEVA 7
  • SBAC 15
  • Target Price
  • TEVA $25.86
  • SBAC $239.87
  • AVG Volume (30 Days)
  • TEVA 14.1M
  • SBAC 1.1M
  • Earning Date
  • TEVA 11-05-2025
  • SBAC 11-03-2025
  • Dividend Yield
  • TEVA N/A
  • SBAC 2.30%
  • EPS Growth
  • TEVA N/A
  • SBAC 25.44
  • EPS
  • TEVA 0.62
  • SBAC 7.95
  • Revenue
  • TEVA $16,776,000,000.00
  • SBAC $2,789,256,000.00
  • Revenue This Year
  • TEVA $4.11
  • SBAC $6.84
  • Revenue Next Year
  • TEVA $0.40
  • SBAC $2.41
  • P/E Ratio
  • TEVA $39.23
  • SBAC $24.29
  • Revenue Growth
  • TEVA 0.02
  • SBAC 4.82
  • 52 Week Low
  • TEVA $12.47
  • SBAC $185.45
  • 52 Week High
  • TEVA $26.38
  • SBAC $245.16
  • Technical
  • Relative Strength Index (RSI)
  • TEVA 66.17
  • SBAC 43.73
  • Support Level
  • TEVA $24.01
  • SBAC $194.35
  • Resistance Level
  • TEVA $26.38
  • SBAC $198.39
  • Average True Range (ATR)
  • TEVA 0.91
  • SBAC 4.17
  • MACD
  • TEVA -0.08
  • SBAC -0.29
  • Stochastic Oscillator
  • TEVA 55.03
  • SBAC 7.41

About TEVA Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

About SBAC SBA Communications Corporation

SBA Communications owns a portfolio of about 45,000 wireless towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by the top few mobile carriers. It owns more than 17,000 towers in the US, which account for about 75% of leasing revenue. Internationally, SBA's largest presence is in Brazil, where it owns roughly 10,000 towers. SBA operates as a real estate investment trust.

Share on Social Networks: